FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 524 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Man Spent 20 Years Tracking Down And Buying His Late Mother’s... October 30, 2021 11 Children Orphaned and Unable to Pay for Funeral After Their... April 25, 2019 Oral Cancer Taught Me How Much Words Matter April 21, 2021 New Low-Powered Implantable Device Monitors Soft Tissue for Signs of Breast... July 1, 2021 Load more HOT NEWS Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... Exercising Safely During Breast Cancer Treatment: What to Know Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide
